Clinical Study
Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma
Table 6
Univariate analysis (Life table & Logrank) and multivariate analysis (Cox regression) of survival.
| Univariate analysis |
| | | Median Survival (months) | Significance |
| Sex | Male | 8 | | Female | 9 | |
| Age | 0–39 | 9 | | 40–59 | 9 | | 60+ | 7 | |
| Histology | Leiomyosarcoma | 9 | Synovial versus the rest | Synovial | 12 | Liposarcoma | 11 | Other | 7 |
| Disease | Locally Advanced | 8 | | Metastatic—single organ | 9 | | Metastatic—multiple organs | 8 | |
| Sites of metastases | Involved versus uninvolved | | | Lung | 7 versus 10 | | Liver | 8 versus 8 | | Bone | 12 versus 8 | |
| Multivariate analysis |
| | Relative risk | 95% CI | Significance |
| Histology | | | | Synovial | 0.6 | 0.5–0.9 | | Other histology | 1.0 | |
| Site | | | | Not involved | 1.0 | 1.1–1.7 | | Involved | 1.4 |
| Chemotherapy | | | | Combination | 0.6 | 0.4–0.9 | | Single agent/Phase I | 1.0 |
|
|